Raghuram Selvaraju, M.B.A. | Managing Director, Senior Analyst, Healthcare
Rodman & Renshaw

Raghuram Selvaraju, M.B.A., Managing Director, Senior Analyst, Healthcare, Rodman & Renshaw

Dr. Raghuram Selvaraju, Ph.D., MBA, currently serves as a Managing Director and Senior Healthcare Analyst at Rodman & Renshaw Research, a unit of H.C. Wainwright & Co. Earlier, he started his sell-side research analyst career with Rodman & Renshaw in 2005. Prior to rejoining Rodman, he served as a Managing Director and Senior Healthcare Analyst at MLV & Co., LLC, till August 2015. Prior to this, Dr. Selvaraju was Managing Director, Head of Healthcare Equity Research and Director of Research at Aegis Capital Corp. from March 2012 until October 2014. Before that, he served as a biotech analyst at Morgan Joseph TriArtisan LLC and Noble Financial Group, Inc. From January 2009 to May 2010, he was Senior Vice President and Head of Healthcare Equity Research at Hapoalim Securities USA, Inc. He is currently Chairman of THERAMetrics Holding AG, a Swiss exchange-listed publicly-traded biotechnology company. Dr. Selvaraju previously was a pharmaceutical researcher at the Serono Pharmaceutical Research Institute, based in Geneva, Switzerland, from January 2000 to April 2004. He holds a Ph.D. in molecular neuroscience and cellular immunology, along with a Master's degree in molecular biology, from the University of Geneva in Switzerland. Dr. Selvaraju obtained his bachelor's degree in biochemistry and technical writing from Carnegie-Mellon University in Pittsburgh, PA, and his MBA from the Johnson Graduate School of Management at Cornell University in Ithaca, NY. He has made numerous media appearances on Bloomberg News, Business News Network and CNBC, among others, and is widely quoted in various industry and mass media publications, including BioCenturyThe Pink Sheet, and The Wall Street Journal.


Day 2 Orphan 15th Nov @ 13:35

Chair opening remarks

Day 2 Orphan 15th Nov @ 13:40

Investor panel: Hear how different investors decide on who and what they invest in, and why

  • What stage do they invest in biotechs and why?
  • How much clinical data do they need to demonstrate?
  • What terms do VCs look for to invest?
  • What could a biotech demonstrate to investors earlier to gain their support?

back to speakers